Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis

@article{Sica2005PharmacokineticsAP,
  title={Pharmacokinetics and Pharmacodynamics of Mineralocorticoid Blocking Agents and their Effects on Potassium Homeostasis},
  author={D. Sica},
  journal={Heart Failure Reviews},
  year={2005},
  volume={10},
  pages={23-29}
}
  • D. Sica
  • Published 2005
  • Medicine
  • Heart Failure Reviews
Spironolacotone and eplerenone are mineralocorticoid-blocking agents used for their ability to block both the epithelial and non-epithelial actions of aldosterone. Spironolactone is a non-selective mineralocorticoid receptor antagonist with moderate affinity for both progesterone and androgen receptors. The latter property increases the likelihood of endocrine side effects with spironolactone including loss of libido, menstrual irregularities, gynecomastia and impotence. Eplerenone is a next… Expand
143 Citations
Mineralocorticoid Receptor Antagonists for Treatment of Hypertension and Heart Failure.
  • D. Sica
  • Medicine
  • Methodist DeBakey cardiovascular journal
  • 2015
  • 13
Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
  • 11
The risks and benefits of aldosterone antagonists
  • D. Sica
  • Medicine
  • Current heart failure reports
  • 2005
  • 16
Pharmacological treatment of aldosterone excess.
  • 17
  • Highly Influenced
Comparison of agents that affect aldosterone action.
  • 26
Mineralocorticoid receptor antagonists: their use and differentiation in Japan
  • A. Sato
  • Medicine
  • Hypertension Research
  • 2013
  • 12
  • PDF
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Aldosterone antagonists in hypertension and heart failure.
  • 53
  • PDF
The 45-year story of the development of an anti-aldosterone more specific than spironolactone
  • J. Ménard
  • Medicine
  • Molecular and Cellular Endocrinology
  • 2004
  • 87
Amiloride, spironolactone, and potassium chloride in thiazide‐treated hypertensive patents
  • 61
Aldosterone and aldosterone antagonism in cardiovascular disease: focus on eplerenone (Inspra).
  • 37
Aldosterone-receptor antagonism and end-stage renal disease
  • 19
Aldosterone and aldosterone antagonism in systemic hypertension
  • 15
Efficacy of low-dose spironolactone in subjects with resistant hypertension.
  • 456
  • PDF
Interactions of Aldosterone Antagonist Diuretics with Human Serum Proteins
  • 18
Pharmacokinetics of spironolactone after a single dose: evaluation of the true canrenone serum concentrations during 24 hours.
  • 21
Spironolactone: A Re-Examination
  • 17
...
1
2
3
4
5
...